We're hiring! 📢
Our team is looking for a Full Stack Biologist driving research at the interface of computational & lab biology. Consider applying if you want to better understand the causal mechanisms of disease using multi-modal, realistic primary cell models. ⚙️ 🧬 💡
Apply here ➡️ lnkd.in/dBuA73nG
This approach is built for curative intent, not chronic management. It's a patient-first, clinically linked approach to I&I discovery. And we're quickly advancing candidates into validation.
View our full poster here 👉 www.graphtx.com/articles/aai...
The crux of our work is a generalized approach that merges large-scale functional profiling with sparse transcriptomic data. By combining functional responses with existing priors, we identify context-dependent, biomarker-stratified targets. 🎯
FIM (Functional Immune Manifold) is Graph's platform that fuses functional perturbation of patient immune cells with multi-omics data to map immune dysfunction and uncover clinically positioned, therapeutically tractable biology in immune diseases.
Today's rheumatoid arthritis (RA) therapies only slow disease. The next generation needs to cure it, and that first requires a comprehensive map of immune dysfunction. At IMMUNOLOGY2026, Graph's co-founder & VP Immunology Christophe Boudesco presented the latest results from our platform FIM. 🏗️ ⚙️
Read more about the Parse x Graph partnership in the comments. 👇
www.parsebiosciences.com/news/parse-b...
Attending IMMUNOLOGY2026? Stop by the Parse x Graph happy hour to talk science & to celebrate our joint partnership to create one of the largest & most comprehensive immune cell perturbation atlases. 🧬🔍
📆 16 April 2026, 19:00
📍 Trillium Brewing Fort Point
🎟️ RSVP: lnkd.in/d7sbWbEA
💡 Poster: Functional Profiling of Rheumatoid Arthritis Reveals Disease-Specific Immunomodulatory Responses and Novel Therapeutic Targets [no. 151]
📍 Computational and Systems Immunology I, Exhibit Hall
📅 16 April 2026, 11:30 - 12:30
💬 Presenting author: Christophe Boudesco
Hey Boston, we’ll be attending #IMMUNOLOGY2026 from 16 - 19 April! Connect with us over our work in immune dysfunction mapping for next generation drug discovery in rheumatoid arthritis.
🔔 Please arrive by 13:25. Representatives will be at the entrance to provide building access.
Join us for a guest talk with @psl-schaefer.bsky.social (@saezlab.bsky.social, Uni Heidelberg)!
💬 Machine Learning for Cellular Perturbations at Scale: Current Capabilities, Limits, and Open Questions
📆 17 March 2026, 13:30 - 14:30
📍 LBI NetMed, Julius-Tandler-Platz 3, Top 5.1, 1090 Vienna
Meet the team behind Graph and say hello to Rin Okumura, Senior Scientist! 🧗⛷️
With Rin on the team, we’re scaling lab-in-the-loop discovery by translating complex biology to high-throughput automated workflows. ➕✖️
A tremendous thank you to the team at Bleed Design Studio for their fresh ideas and precise implementation of helping us visualize the complexity of our work!
New look, same mission. 🧑🚀 🚀
We’re excited to debut our updated website that reflects who we are and the work we are doing at Graph: unafraid and boldly confronting the dynamic behavior of immune biology head on.
Check it out 🌐 www.graphtx.com
Thanks to the organizers of this Keystone Symposia meeting! We’re already looking forward to the next one. ➕✖️
To better understand how immune cells jointly behave in a complex inflammatory environment, the Graph team profiled millions of primary-immune cells in a disease-relevant systemic inflammation condition, and identified numerous hits that affect inflammasome modulation in monocytes. 📊 💡
Focusing on the NLR-specific endpoint of endogenous ASC-speckling in sterile inflammation, we mapped systemic responses by using our platform for fast, patient-first I&I discovery. 🗺️ 📍
In our latest talk & poster presentation at the Keystone Autoimmunity & Autoinflammation symposium, Graph’s co-founder & CSO Bojan Vilagos presented our generalizable & scalable approach for discovering shared mechanisms across disease contexts. 🧬 ⚙️
Full poster here 👉 graphtx.com/inflammasome...
Together with Parse’s GigaLab technology that can profile hundreds of millions of cells and Graph’s lab-in-the-loop platform that can systematically select and test perturbations across a wide range of disease contexts, we are reshaping the future of AI-first drug discovery. ➕✖️
Immune-mediated & autoimmune diseases are notoriously difficult to model. By leveraging primary patient-derived cells rather than cell lines or animal models, this partnership allows the team at Graph to identify the most promising disease mechanisms, drug targets, & biomarkers early in discovery.
Parse Biosciences and Graph are partnering to create the world's most comprehensive immune cell perturbation atlas aimed at revealing immune system dysfunction for curative drug discovery. 🧬 🗺️
➡️ Read more: www.parsebiosciences.com/news/parse-b...
Together with Parse’s GigaLab technology that can profile hundreds of millions of cells and Graph’s lab-in-the-loop platform that can systematically select and test perturbations across a wide range of disease contexts, we are reshaping the future of AI-first drug discovery. ➕✖️
Immune-mediated & autoimmune diseases are notoriously difficult to model. By leveraging primary patient-derived cells rather than cell lines or animal models, this partnership allows the team at Graph to identify the most promising disease mechanisms, drug targets, & biomarkers early in discovery.
Fantastic panel at the Evotec Breakfast Reception in SF! Graph co-founder @gregvladimer.bsky.social shared insights alongside leaders from @isomorphiclabs.bsky.social & @medra-ai.bsky.social about how AI helps to unlock disease mechanisms & supports the development of future bio discoveries. 🚀
Poster title:
“Functionally-Guided Multiomics Profiling of Human Systemic Inflammation Identifies Myeloid Therapeutic Targets”
📍 Poster session 1
📅 20 January 2026
💬 Presenting author: Bojan Vilagos
🏔️ Hey Colorado, we’ll be up in the Rockies from 19 - 22 January 2026 for the Autoimmunity & Autoinflammation symposium! We’re looking forward to showcasing our approach of using advanced imaging & data modeling to find clinically-relevant targets & pathways for immune diseases in our latest poster.
🌊 ⛵ Hey San Francisco, on 13 January 2026 adjacent to the 44th Annual JPM Healthcare Conference, Graph’s co-founder and CEO Greg Vladimer will be speaking on Evotec's panel “Precision at Scale: AI’s impact on Drug Discovery." Let us know if you are in San Francisco and let’s talk techbio!
Just last week, we had a group retreat (aka Graph Con) to a mountain hut in the Alps 🇦🇹. We spent some time honing our cooking skills, enjoying the wintry landscape, and forging our 2026 strategy around immune dysfunction mapping.
We’re already energized for 2026, and we’re just getting started. 💫
Thank you to everyone who attended our AI x Bio meetup last week in Berlin! We had a great time catching up with old friends and making new connections. 🪩 🕺
👏 A huge thank you to all of our cohosts, including @Merantix AI Campus, Merantix Capital, CytoData, and @techbio.bsky.social support!
